Sass & Sass, Inc. has a robust pipeline with three new products accepted for the regulation by the USDA.
New products development:
938001 is a new candidate which we started testing for feline infectious peritonitis. The formulation was developed after the success in our preliminary research in FIP published by Dr. Legendre and Dr. Perkins. Currently, we are manufacturing experimental serials of the product and continue tests with a small group of veterinarians and researchers.
938002 is a new candidate formulated as topical ocular drops to treat ocular disease caused by the feline herpesvirus. The preliminary clinical safety trials have been completed at the University of Tennessee-Knoxville by Dr. D. Hendrix, who showed that the proposed formulation is safe for the application. The results were presented at the meeting of the American College of Veterinary Ophthalmologists in Baltimore, MD, on October 2017.
SSS07 is a new candidate positioned for treating of immune and virus-related skin disease in cats. The preliminary safety studies showed its safety in several species, and we are planning to expand the trials. After the delays caused by COVID-19, the company plans to move ahead with 938001 and 938002, starting the field trials in 2021. The note of the trials will be published on our website and other platforms.
Please note that under their ethics in clinical trials guidelines, Sass & Sass, Inc. believes that study animals should not be euthanized but should be provided a chance through adoption and be treated like any owned pet. Sass & Sass, Inc. does not purposely infect animals with fatal diseases and does not support any research that does.
A small pilot study of the use of Polyprenyl Immunostimulant in the outbreak of canine distemper in ferrets was conducted with Polyprenyl Immunostimulant by the Ferret Association of Connecticut.
After receiving field reports of several cases of feline panleukopenia successfully treated with Polyprenyl Immunostimulant, Sass & Sass is planning to look into the feasibility of formulating and testing a new product for the disease.
• Other retroviral diseases that affect the immune system in cats, including feline leukemia and FIV.
Numerous field reports showed a potential utility of a new product based on Polyprenyl Immunostimulant for the FeLV and FIV.